Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial seeks to accomplish both local and regional control of head and neck cancer and reduce systemic metastatic disease. To do this, patients will received chemotherapy followed by chemotherapy and radiation (given together) with an escalating dose of docetaxel.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Alabama at Birmingham
• Collaborator: Aventis Pharmaceuticals
• Treatments: Amifostine; Cisplatin; Docetaxel

Criteria

Inclusion Criteria:

• The patient has histologically proven primary or recurrent squamous cell carcinoma arising in the oropharynx, oral cavity, hypopharynx, larynx, or nasopharynx.

• The patient has stage III or IV disease.

• Performance status < 2 (ECOG scale) with a life expectancy of > 12 months.

• Age 19 years and above.

• The patient is medically fit to tolerate a course of definitive radiation therapy.

• The patient has:

1. adequate hepatic function with bilirubin < upper limit of normal (ULN)

2. transaminases (SGOT and SGPT) may be up to 2.5 x ULN if alkaline phosphatase is < ULN, or alkaline phosphatase may be up to 4 x ULN if transaminases are < ULN

3. adequate renal function with serum creatinine < 1.5 mg/dl (or estimated creatinine clearance of > 50 mL/min)

4. normal serum calcium

5. adequate hematologic function as: defined by an absolute neutrophil count > 1500/ml, hemoglobin > 8.0 g/dl, and platelet count > 100,000/ml.

• The patient may have had a prior malignancy but must be three years from treatment.

• A history of superficial non-melanoma skin cancer or in situ carcinoma of the cervix less then three years will be allowed.

• The patient must agree to use effective contraception if procreative potential exists, and continue contraception for at least 6 months following completion of the study.

• Patient must sign informed consent.

Exclusion Criteria:

• The patient has received radiation therapy previously to the head and neck.

• The patient has received prior chemotherapy for head and neck cancer.

• The patient is pregnant or lactating.

• Peripheral neuropathy > Grade 2.

• Serious non-malignant disease (e.g. congestive heart failure, uncontrolled atrial fibrillation, active hepatitis).

• Any underlying psychological condition that would prohibit the understanding and rendering of informed consent.

• Patients with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80 must be excluded.